elsulfavirine + rifabutin

Elsulfavirine + rifabutin is a combination regimen investigated for the management of HIV-1 infection in patients co-infected with mycobacterial diseases such as tuberculosis. Elsulfavirine, developed by Viriom, is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that acts as a prodrug of VM-1500A. It is characterized by a high genetic barrier to resistance and a long half-life, allowing for once-daily or potentially less frequent dosing. Rifabutin is a rifamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase. This specific combination is of clinical interest because rifabutin is a significantly weaker inducer of the CYP3A4 enzyme compared to rifampicin, potentially allowing for safer co-administration with NNRTIs like elsulfavirine without requiring the substantial dose adjustments often necessary with other rifamycins.

Brand names

ElpidaMycobutin

Other names

VM-1500AVM1500AVM 1500Aelsulfavirine and rifabutin